Semaglutide and Sudden Vision Loss
Quick Facts
What is NAION and why is it appearing in GLP-1 drug labels?
Non-arteritic anterior ischemic optic neuropathy (NAION) is sometimes described as a stroke of the optic nerve. Reduced blood supply damages the nerve head, typically causing sudden, painless vision loss in one eye, often noticed on waking. It is the most common acute optic neuropathy in adults over 50. Known risk factors include diabetes, hypertension, sleep apnea, high cholesterol, and a crowded optic disc anatomy sometimes called a "disc at risk." There is no proven cure, and vision lost to NAION is often only partly recovered.
Concern about GLP-1 receptor agonists grew after observational studies, including work published in JAMA Ophthalmology in 2024 by researchers at Mass Eye and Ear, reported a higher incidence of NAION among people prescribed semaglutide compared with other glucose-lowering or weight-loss medicines. Further cohort studies reached varying conclusions on the size of the increase. In mid-2025, the European Medicines Agency's safety committee concluded that NAION should be listed as a very rare side effect of semaglutide, meaning fewer than 1 in 10,000 users. Updated labelling in other jurisdictions follows the same principle: clinicians and patients should be told about the signal even though causation is not fully settled.
How strong is the evidence linking weight-loss drugs to vision problems?
Most data come from large health-record and claims databases rather than randomized trials, which were not designed or powered to detect a condition this rare. Observational analyses can be confounded because people prescribed these drugs often already have diabetes, obesity, hypertension, or sleep apnea, which are themselves NAION risk factors. Some studies found a clearly elevated relative risk, while others found a smaller or less certain increase. Even where the relative risk is higher, the absolute number of affected people remains small.
Eye health has been a separate topic in semaglutide research for some time. In the SUSTAIN-6 cardiovascular outcomes trial, published in the New England Journal of Medicine in 2016, retinopathy complications were more frequent with semaglutide than placebo in people with type 2 diabetes, a finding linked to rapid blood-glucose lowering in those with existing retinal disease. Researchers continue to study whether the mechanisms behind that signal and NAION overlap, but no unifying explanation has been established. Possible hypotheses include changes in blood pressure or blood flow during rapid weight loss, though none is confirmed.
What should patients taking GLP-1 medicines do now?
For the great majority of patients, the established benefits of these medicines, including improved glycemic control, weight loss, and, for some products, reduced cardiovascular events, remain important. The label update is intended to improve awareness rather than signal that the drugs should be avoided. Patients with existing optic nerve disease, a prior episode of NAION, or other significant eye conditions should discuss individual risk with their prescriber and eye specialist. People with diabetes should keep up regular dilated retinal screening, especially when starting treatment that lowers glucose quickly.
Any sudden change in vision, such as a dark or blurry patch, loss of part of the visual field, or reduced sharpness in one eye, warrants urgent evaluation by an ophthalmologist or emergency department the same day. Early assessment can rule out other treatable causes, such as retinal detachment or giant cell arteritis, which also causes vision loss and needs prompt treatment. Clinicians are also encouraged to report suspected adverse events to national pharmacovigilance systems, since these reports help regulators refine risk estimates.
Frequently Asked Questions
No. Observational studies and regulator reviews suggest a possible association with NAION, which is considered very rare, but a causal relationship has not been proven. Many people who develop NAION have other risk factors such as diabetes, hypertension, or sleep apnea.
Do not stop on your own. Talk to your prescriber, especially if you have had an optic nerve problem or other serious eye disease. Stopping treatment can carry its own health risks.
Typical signs are sudden, painless loss of vision or part of the visual field in one eye, often noticed on waking. Seek urgent medical care if this happens.
Regular dilated eye exams are recommended for everyone with diabetes. Those with existing retinopathy should discuss monitoring with their care team when starting a medicine that lowers glucose quickly.
References
- European Medicines Agency, Pharmacovigilance Risk Assessment Committee. Review of semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION). 2025.
- Hathaway JT, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmology. 2024.
- Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
- Association of Optometrists (AOP). FDA requires updated safety labelling for weight-loss medication. November 2026.